Amyloidosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TTR 56
• BCMA 11
• APOE 0
• SGLT2 0
• CD19 4
• MAPT 0
• CD38 0
• TNF 0
• APP 0
• BCL-2 0
• RET 0
• SNCA 0
• TREM2 0
• GPRC5D 2
• IL-1 0
• IL-6 0
• JAK 0
• LAG-3 0
• PPAR 0
• BACE1 0
• CFTR 0
• CXCR4 0
• EGFR 0
• HIF-1 0
• NRF2 0
• PARP 0
• PI3K 0
• TLR4 0
• TP53 0

24 of 82+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · R01

  Gene therapy using Reelin fragments in mouse brain

  Henry Ford Health + Michigan State University Health Sciences· East Lansing, United States· US$654,111 awarded in fiscal year 2026· until Jun 2031

• NIH NIA · F30

  Deciphering the roles of APOE4 and amyloid-beta in Alzheimer's disease progression

  University of California-Irvine· Irvine, United States· US$47,896 awarded in fiscal year 2026· until Jun 2029

• NIH NIA · R21

  Lysosomal dysfunction as a risk factor in Alzheimer disease

  University of Illinois at Chicago· Chicago, United States· US$240,495 awarded in fiscal year 2026· until May 2028

• NIH NIA · R56

  The role of CLU in molecular pathogenesis of Alzheimers disease

  Translational Genomics Research Inst· Phoenix, United States· US$798,749 awarded in fiscal year 2026· until Aug 2027

• NIH NIA · R43

  Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease

  Mindimmune Therapeutics, Inc.· Kingston, United States· US$496,415 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €217,965· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis (MONSil-AD)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,482,666· until Dec 2030

• European Commission (Horizon 2020) · ERC-COG

  A unified drug discovery platform for protein misfolding diseases (ProMiDis)

  Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk· Vari-Athens, Greece· EU contribution €1,972,000· until Feb 2027

9 of 305 running projects, newest first. Listed amounts together: US$226.6m + €3.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-Label Study of AG10 in Patients With Cardiomyopathy

  NCT03536767· Eidos Therapeutics, a BridgeBio company· Updated 14 Oct 2026

  “Study ended by the sponsor due to meeting Study Objectives”Registry text, quoted unchanged. Source

• Withdrawn

  ION-682884 in Patients With TTR Amyloid Cardiomyopathy

  NCT04843020· Brigham and Women's Hospital· Updated 20 Feb 2026

  “no subjects available”Registry text, quoted unchanged. Source

• Terminated

  Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  NCT06338839· AstraZeneca· Updated 18 Sept 2025

  “The study was suspended after interim analysis to confirm reasonability of further investigation of the population”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

  NCT04569903· Yale University· Updated 18 Sept 2025

  “No patients consented to enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

  NCT04418024· Eidos Therapeutics, a BridgeBio company· Updated 19 Sept 2024

  “After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

  NCT04882735· Eidos Therapeutics, a BridgeBio company· Updated 19 Sept 2024

  “Sponsor's decision to cancel study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Alnylam Pharmaceuticals Inc.· Source

• Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

  NCT05974644· Virginia Commonwealth University· Source

• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Alnylam Pharmaceuticals· Source

• PET/CT Imaging in Carriers of TTR Mutations

  NCT07591038· University of Texas Southwestern Medical Center· Source

• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Alexion Pharmaceuticals, Inc.· Source

• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Alnylam Pharmaceuticals· Source

• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Novo Nordisk A/S· Source

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Alnylam Pharmaceuticals· Source

• A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Novo Nordisk A/S· Source

• TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Alnylam Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 3
• Gene Expression Profiling 3
• Sequence Analysis, RNA 3
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 2
• Mass Spectrometry 14
• Flow Cytometry 1
• Immunohistochemistry 14
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 95
• Machine Learning 13
• Deep Learning 4
• Cohort Studies 42
• Genome-Wide Association Study 2

• Small Molecule Stabilization of Diverse Amyloidogenic Immunoglobulin Light Chains Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry.

  J Mol Biol, Jun 2026

• Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling.

  Cardiovasc Pathol, Jun 2026

• Amyloid in Primary Hip Arthroplasty Specimens: An Opportunity for Early Detection of Amyloidosis?

  J Arthroplasty, May 2026

• Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis.

  Anal Chem, Mar 2026

• Tissue characterization in cardiac amyloidosis: a joint consensus document by the gruppo di studio di cardiopatologia (SIAPEC) and the SIC/ANMCO Italian cardiac amyloidosis network (RIAC).

  J Cardiovasc Med (Hagerstown), Jan 2026

• Multiplexed Isotope-Coded Mass Spectrometry Footprinting Enables Broad Heteroatom-Residue Mapping and Uncovers Noncanonical Ligand-Binding Sites in Amyloidosis Proteins.

  Anal Chem, Jan 2026

• Mini review on the laboratory diagnosis of amyloidosis: An overview of methods, applications, and trends in analytical approaches.

  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, Jan 2026

• Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations.

  Proc Natl Acad Sci U S A, Dec 2025

• A Covalent Protein Painting Assay Differentiates Amyloid-β Polymorphs in Alzheimer Disease.

  J Proteome Res, Dec 2025

• Validation of a Mass Spectrometry-Based Proteomics Molecular Pathology Assay.

  Mol Cell Proteomics, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.